
USD
+$0.00
(+0.00%
)At Close (As of Dec 12, 2025)
$709.76M
Market Cap
-
P/E Ratio
-22.75
EPS
$34.43
52 Week High
$7.65
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $61K |
| Total Revenue | $61K |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$359M |
| Selling General And Administrative | $52M |
| Research And Development | $172M |
| Operating Expenses | $359M |
| Investment Income Net | - |
| Net Interest Income | $24M |
| Interest Income | $24M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $20M |
| Income Before Tax | -$343M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$343M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$220M |
| Ebitda | -$201M |
| Net Income | -$343M |
| Field | Value (USD) |
|---|---|
| Total Assets | $491M |
| Total Current Assets | $380M |
| Cash And Cash Equivalents At Carrying Value | $106M |
| Cash And Short Term Investments | $106M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $111M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $32M |
| Short Term Investments | $265M |
| Other Current Assets | $9.1M |
| Other Non Current Assets | - |
| Total Liabilities | $108M |
| Total Current Liabilities | $54M |
| Current Accounts Payable | $5.4M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $8M |
| Total Non Current Liabilities | $54M |
| Capital Lease Obligations | $59M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $59M |
| Other Current Liabilities | $40M |
| Other Non Current Liabilities | $3.3M |
| Total Shareholder Equity | $383M |
| Treasury Stock | - |
| Retained Earnings | -$1.3B |
| Common Stock | $29K |
| Common Stock Shares Outstanding | $13M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $61K |
| Total Revenue | $61K |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$359M |
| Selling General And Administrative | $52M |
| Research And Development | $172M |
| Operating Expenses | $359M |
| Investment Income Net | - |
| Net Interest Income | $24M |
| Interest Income | $24M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $20M |
| Income Before Tax | -$343M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$343M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$220M |
| Ebitda | -$201M |
| Net Income | -$343M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Lyell Immunopharma, Inc. is a cutting-edge biopharmaceutical company headquartered in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington. The company specializes in pioneering T-cell reprogramming technologies designed to formulate innovative therapies targeting solid tumors, thereby enhancing the effectiveness and longevity of T-cell treatments. With its proprietary platforms and a strong commitment to meeting significant unmet medical needs in oncology, Lyell is well-positioned to transform cancer treatment and play a critical role in the evolving immuno-oncology sector.